Clinical Trial Duration: How Long Each Phase and Type Takes

Introduction

If you’ve ever wondered how long clinical trials take, you’re far from alone. Whether you’re a patient exploring participation, a physician partnering on research, or a sponsor planning a development program, the timeline question shapes nearly every decision you’ll make.

The short answer: the total duration of a clinical trial process typically spans 6 to 7 years on average for the clinical phases alone. But depending on the disease, treatment type, and regulatory path, clinical trials may take 10 to 15 years to complete from initial preclinical research to market availability.

This guide breaks down the duration of each clinical trial phase, the factors that affect speed, and how to estimate the timeline that applies to your specific situation.

Understanding Clinical Trial Timelines

The clinical trial progression includes sequential phases designed to test safety and effectiveness. But those three phases-plus the preclinical work before them and the post-market monitoring after-don’t unfold on a fixed schedule. Duration varies dramatically based on what’s being tested, who it’s being tested on, and where the trials are conducted.

Here’s the overall picture of the complete process:

• Preclinical research: 3–6 years of laboratory work, animal studies, and toxicology testing before any drug is tested in the human body.
• Clinical trial phases (I–III): Roughly 6–7 years on average from first human dose to regulatory submission, though this range spans from under 3 years to over 15 years.
• Regulatory review: Approximately 1 year under standard FDA review, faster under priority or accelerated pathways.
• Phase IV / Post-market: Ongoing for years to decades.

A U.S. Health & Human Services report estimates the “clinical testing to marketing” timeline at roughly 90.3 months-about 7.5 years for many drugs. Adding preclinical studies pushes total development closer to 10–12 years for complex therapeutic areas like CNS and cardiovascular disease.

One important clarification: the treatment’s phase during trials indicates its scientific purpose, not necessarily the timeline duration. A Phase I trial isn’t always the fastest, and a Phase III isn’t always the slowest. Phases of clinical trials can overlap, affecting the overall timeline-some sponsors begin Phase II planning before Phase I is fully complete, and adaptive designs can blur traditional boundaries.

It’s also worth noting that screening or prevention trials often take longer than treatment trials. Screening trials require extended follow-up to determine whether early detection strategies actually improve long-term outcomes, while treatment trials focus on more immediate efficacy signals—topics we address in more detail in our frequently asked questions about clinical trials.

At Advanced Research Institute, we’ve seen firsthand how thoughtful trial design and efficient site operations can shave months off projected timelines-without compromising the rigorous safety standards that protect participants.

How We Evaluated Trial Duration Factors

To provide accurate timeline estimates, we analyzed the factors that most consistently affect how long trials take across therapeutic areas and phases. Here are the six dimensions we evaluated:

Patient enrollment speed and availability. Patient recruitment is often the biggest bottleneck in clinical research. Enrollment challenges can consume up to 30% of the entire development timeline. Finding enough patients who meet eligibility criteria-especially for rare diseases-drives timelines more than almost any other single factor. Funding availability can also affect the timeline of clinical trials, particularly for smaller sponsors who depend on enrollment milestones to release funding tranches.

Regulatory review and approval timelines. Regulatory approvals can add time to the start of clinical trials. IRB review, IND applications, import licenses for investigational products, and country-specific ethics committee reviews all introduce lead time before a single participant is enrolled. One study found central IRB review took a median of 78 days versus 165 days for local review boards.

Safety monitoring and data collection requirements. The complexity of drug treatments and disease types influences the duration of trials. Treatments requiring intensive monitoring, frequent lab draws, or specialist equipment demand more per-visit time and longer observation windows.

Disease complexity and treatment type. Slowly progressing diseases (neurodegenerative conditions, certain cancers) require years of follow-up to detect meaningful changes. The validation process in clinical trials must account for this complexity.

Follow-up period requirements. Follow-up periods can last from a few months to over 10 years, depending on endpoints. Trials measuring overall survival or long term side effects need considerably more time than those using biomarker surrogates.

Geographic scope and site coordination. International trials must navigate disparate regulatory, legal, and logistical environments. Data management and site operation complexities can introduce delays in clinical trials, particularly when coordinating across dozens of sites in different countries.

Clinical Trial Phases Ranked by Duration

1. Phase I Trials

Phase I trials are the first step in testing a new drug or new treatment in people. The primary trials focus on determining a drug’s safety profile-how the human body processes the compound, what a single dose does at various levels, and what happens as doses increase.

Why it stands out: Phase I represents the shortest clinical phase, but it lays the critical foundation for everything that follows. Without clean safety data here, no subsequent research moves forward.

Best for: First-in-human studies and dose-finding protocols where researchers need to establish how a drug behaves in real biological systems.

Key timeline characteristics:

• Duration: Phase I trials typically last several months, though oncology I trials can stretch to 1–3 years
• Participants: Phase I trials involve 20 to 100 healthy volunteers (or patients in oncology settings)
• Focus: Safety, tolerability, pharmacokinetics
• About 70% of drugs pass Phase I trials and advance to the next stage

The study team closely monitored participants during this phase through frequent visits. One analysis of oncology Phase I trials found that individual participation lasted a median of 2.5 months, but the overall trial from activation to completion spanned roughly 32 months.

Possible delays: Unexpected adverse events can lead to trial pauses while investigations occur. If a drug causes too many side effects at a given dose, the protocol may require adjustment, adding weeks or months. Dosage adjustments and the need for additional safety cohorts also extend timelines.

2. Phase II Trials

Phase II moves beyond basic safety into effectiveness territory. This is where researchers begin testing whether the treatment works against the intended disease. The research team evaluates different groups of patients at various dose levels, looking for signals that the drug produces meaningful clinical improvement.

Why it stands out: Phase II strikes a balance-long enough to generate meaningful efficacy data, but shorter than the large-scale Phase III confirmatory studies. It’s where a pharmaceutical company first learns whether its promising compound might actually deliver results.

Best for: Proving concept and refining treatment protocols before committing to expensive, large-scale trials.

Key timeline characteristics:

• Duration: Phase II trials typically last from several months to two years
• Participants: Several hundred patients, often across multiple sites
• Focus: Efficacy, dose-ranging, side effect monitoring
• Approximately 33% of drugs pass from Phase II to Phase III-this phase has one of the steepest attrition rates

During Phase II, the protocol often includes comparison against a placebo or inactive substance to determine whether the treatment produces effects beyond what would occur naturally. Controlled clinical trials at this stage use randomization to assign participants to different groups, and many employ double blind methodologies where neither the study team nor patients know who receives the active drug, reflecting the central role of placebos in clinical research.

Possible delays: Recruitment challenges are common in Phase II, especially when the target population is narrowly defined. Assessment of efficacy signals may require additional time if initial data is ambiguous-researchers must determine whether early results justify the investment of a Phase III program.

3. Phase III Trials

Phase III trials are the definitive test. These large-scale studies compare the new treatment against existing standard-of-care therapies (or placebo where appropriate) to confirm that the treatment works in a broad population with acceptable safety.

Why it stands out: Phase III is typically the longest and most expensive clinical phase. But successful Phase 3 results are crucial for regulatory approval applications-without them, the path to FDA approval is essentially closed for most drugs.

Best for: Generating the evidence regulators require, comparing a new treatment to what’s currently available, and identifying long term safety signals.

Key timeline characteristics:

• Duration: Phase III trials can last from one to four years for clinical execution alone
• Participants: Phase III trials can involve several hundred to several thousand patients
• Focus: Comparative effectiveness, safety confirmation, benefit-risk assessment
• Only 25 to 30% of drugs pass all clinical trial phases and reach the market

Global data shows that Phase III trial durations are increasing. Median recruitment duration for industry-sponsored Phase III drug trials rose from about 13 months (2008–2011) to 18 months (2016–2019), and total trial duration medians climbed to approximately 28 months in the most recent period.

Possible delays: Complex study designs and difficulties in patient recruitment can significantly delay clinical trials at this stage. Interim analyses may reveal safety concerns requiring protocol amendments. Unexpected problems can delay the completion of trials-anything from supply chain disruptions to changes in regulatory guidance mid-study. In cancer trials, rarer cancers take longer due to fewer available patients who meet eligibility criteria.

4. Phase IV Post-Market Studies

Phase 4 trials are conducted post-marketing to monitor long-term safety and effectiveness. Once a drug receives FDA approval and reaches the market, the research doesn’t stop. Phase IV studies track how the medicine performs in real-world conditions across broader, more diverse populations than clinical research typically enrolls.

Why it stands out: Phase IV has no fixed end date. These studies generate real-world evidence that can confirm a drug’s long-term value-or reveal rare adverse events that only emerge after many years of widespread use.

Best for: Detecting long term side effects, studying drug interactions, evaluating effectiveness in populations not well-represented in earlier trials, and supporting new methods of use or additional indications.

Key timeline characteristics:

• Duration: Years to decades, with no standard endpoint
• Participants: Large populations, often tens of thousands
• Focus: Long-term safety, real-world effectiveness, rare event detection
• Follow-up periods can last from months to over 10 years

Possible delays: Rare event detection inherently requires long observation. Regulatory requirements may mandate specific post-market commitments. Some symptoms or safety signals only become apparent after several years of exposure.

Quick Timeline Comparison of Clinical Trial Phases

Phase	Typical Duration	Participant Count	Primary Focus	Approximate Pass Rate
Phase I	A few months to 1–2 years	20–100	Safety and dosage	~70%
Phase II	Several months to 2 years	100–300+	Efficacy and dose-ranging	~33% advance
Phase III	1–4 years	Hundreds to thousands	Comparative effectiveness	25–30% overall
Phase IV	Years to decades (ongoing)	Thousands+	Long-term safety	N/A (post-approval)
Key takeaways:

• Phase I – Best for quick safety assessment (several months in most cases)
• Phase II – Best for efficacy proof-of-concept (months to 2 years)
• Phase III – Best for regulatory approval data (1–4 years)
• Phase IV – Best for long-term safety data (ongoing, indefinite)

How to Predict Your Clinical Trial Timeline

Understanding the general durations above is useful, but your specific trial timeline depends on several intersecting variables. Here’s how to narrow your estimate.

Choose Based on Disease Prevalence

The availability of eligible patients is the single most powerful predictor of how long trials will run.

• Rare diseases extend recruitment timelines significantly. Among 150 pivotal trials supporting rare disease drug approvals (2013–2022), median sample sizes were just 109 participants-but finding even that many patients for uncommon conditions can take years. Rarer cancers take longer due to fewer available patients in any given geographic area.
• Common conditions allow faster enrollment. Trials for prevalent diseases like hypertension or diabetes can recruit from large patient pools, accelerating the enrollment window from many years down to several months.
• Geographic considerations matter. Advanced Research Institute operates across Utah and Nevada, which allows access to diverse patient populations and supports our role as a clinical trial company in Utah and Nevada. However, for rare diseases, sponsors often need to conduct international trials across dozens of countries to find enough patients-which introduces additional coordination delays.

Prevention trials present their own challenge. Because these studies track whether an intervention prevents disease onset, they require long follow-up in initially healthy populations, making them among the longest clinical study designs—something reflected in many of our ongoing clinical studies across multiple locations.

Choose Based on Treatment Complexity

Not all treatments are created equal when it comes to the time they demand.

• Novel treatment mechanisms require longer safety monitoring. Trials using new treatment methods require more setup time, including additional preclinical studies, manufacturing scale-up, and regulatory consultation. Gene therapies and biologics, for example, often need extended observation periods that small-molecule drugs do not.
• Combination therapies need extended observation. When testing drug combinations, the study team must account for interaction effects, which requires additional testing arms and longer monitoring windows.
• Single dose vs. long-term treatment protocols. A trial evaluating a single dose intervention for an acute condition might complete in a few months. A trial studying a chronic disease medicine administered daily for years will, by definition, require years of treatment exposure data.

Choose Based on Regulatory Requirements

The regulatory path you follow shapes your timeline as much as the science does.

• FDA guidance and approval pathway timelines. The FDA review process can take 6 months to 2 years depending on the pathway. Standard NDA/BLA review follows PDUFA timelines of roughly 10–12 months, while priority review, breakthrough therapy, and fast track designations can compress this substantially.
• Special populations and additional safety requirements. Trials involving pediatric patients, pregnant individuals, or immunocompromised populations typically require additional safety data and ethics review.
• International regulatory coordination. Multinational trials must satisfy each country’s regulatory framework. Disparate requirements for drug testing, labeling, import licenses, and ethics approval create cumulative delays that can add several months to site activation timelines.

Sponsors and CROs selecting trial sites should evaluate site-level efficiency metrics. At Advanced Research Institute, streamlined processes and experienced teams help reduce start-up durations-one of the most controllable delay factors, reflecting our broader mission and history as described on our about our company page.

Which Timeline Applies to Your Situation?

With all these variables in play, here’s a practical framework for estimating where your trial falls:

Choose Phase I timelines if you’re developing first-in-class treatments. Expect several months to 2 years for drug testing in a small group. Budget extra time if your compound uses a novel mechanism or requires specialist equipment for administration and monitoring—and consider how early-phase participation opportunities on our site for those who want to participate in a clinical trial align with these timelines.

Choose Phase II timelines if you’re testing promising therapies with known safety profiles. If your drug has already demonstrated tolerability and you have a clear efficacy hypothesis, plan for several months to two years. The trial design-particularly endpoint selection and whether you can use biomarkers-will determine where you land in that range.

Choose Phase III timelines if you’re seeking regulatory approval. This is where you need to plan for 1 to 4 years of clinical execution. For example, cardiovascular Phase III trials average nearly 40 months, while infectious disease trials may run closer to 35 months. The data you generate here must be comprehensive enough to support an NDA or BLA submission.

Plan for extended timelines if studying rare diseases or complex treatments. If your clinical study targets a small patient population, uses a first-in-class biologic, or requires long-term endpoints, assume the upper end of every range. Some medical breakthroughs took many years to move from laboratory discovery through all three phases to approved treatment-but the impact on patients made every month worthwhile.

Remember: the total time from IND submission to NDA approval averages about 8.7 years in the U.S., with a range spanning from roughly 2 years to over 16 years. Your specific combination of disease area, trial design, regulatory strategy, and operational execution will determine where you fall.

Final Thoughts

So, how long do clinical trials take? The honest answer is that it depends-on the phase, the disease, the drug, the regulatory path, and dozens of operational factors that can either compress or extend timelines.

Here’s what we know with confidence:

• Phase I trials typically run a few months in straightforward cases, longer in oncology
• Phase II spans several months to two years, with a steep attrition rate
• Phase III requires 1 to 4 years and represents the most resource-intensive stage
• Phase IV continues indefinitely after a drug is approved, monitoring real-world safety

The entire process, from preclinical research through regulatory approval, often spans several years-and sometimes well over a decade. But this thorough, closely monitored approach exists for a reason: to determine that every new treatment that reaches patients is both safe and effective.

See If You Qualify For One Of Our Studies

Next Steps

At Advanced Research Institute, we participate in clinical trials across multiple therapeutic areas, bringing efficient site operations, strong participant retention, and experienced research teams to every study we conduct. Whether you’re a patient exploring participation or a sponsor seeking a reliable trial site in Utah or Nevada, understanding these timelines helps you plan with realistic expectations.

If you’re interested in learning more about current studies or exploring how ARI can support your research goals, visit our clinical trials page to begin the conversation, explore options to book a free clinical trial consultation, or contact our research sites directly.